FluoroPharma Medical, Inc. announced the currently acquired imaging data from its ongoing Phase II clinical trial for CardioPET (FCPHA) to assess myocardial perfusion and fatty acid uptake in coronary artery disease (CAD) patients. CardioPET, one of FluoroPharma's first in class PET imaging products, is a perfusion and fatty acid uptake indicator, which is designed to be used as a cardiac imaging agent and may prove to be an effective alternative to currently available diagnostic tests. FluoroPharma believes its pharmacokinetic characteristics could be especially valuable in patients who are unable to exercise.

The ongoing Phase II clinical trial is an open label study designed to assess the safety and diagnostic performance of CardioPET as compared to currently utilized SPECT myocardial perfusion imaging agents and angiography, the current gold standard. This multicenter study is being conducted in Belgium.